chronic severe pain
Pain · 2005–2019
No submission for this condition has carried consumer input, including the 5 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| oxycodone Chronic severe disabling pain unresponsive to non-opioid analgesics. | Jul 2019 | Not recommended | none received |
| buprenorphine Chronic severe disabling pain unresponsive to non-opioid analgesics. The submission sought listing of four additional transdermal patch strengths (15, 25, 30,… | Mar 2015 | Deferred | none received |
| oxycodone hydrochloride + naloxone hydrochloride Chronic severe disabling pain unresponsive to non-opioid analgesics. The submission sought listing of three additional strengths (2.5 mg/1.25 mg, 15 mg/7.5 mg,… | Mar 2015 | Deferred | none received |
| buprenorphine Chronic severe disabling pain unresponsive to non-narcotic analgesics. | Nov 2015 | Recommended | no section in document |
| buprenorphine Chronic severe disabling pain in patients who have achieved a stable dose of buprenorphine patches. | Nov 2015 | Not recommended | none received |
| tapentadol Chronic severe disabling pain not responding to non-narcotic analgesics. | Jul 2012 | Not recommended | unclear |
| tapentadol Treatment of chronic severe disabling pain not responding to non-narcotic analgesics. | Mar 2011 | Not recommended | no section in document |
| oxycodone hydrochloride with naloxone hydrochloride dihydrate Chronic severe disabling pain not responding to non-narcotic analgesics. The naloxone component is indicated for therapy and/or prophylaxis of opioid-induced… | Nov 2010 | Recommended with restriction | no section in document |
| fentanyl Chronic severe disabling pain not responding to non-narcotic analgesics, including both cancer-related and non-cancer pain. | Mar 2006 | Recommended with restriction | no section in document |
| fentanyl Chronic severe disabling pain not responding to non-narcotic analgesics. Extension of current restricted benefit from cancer-only to include non-cancer chronic… | Mar 2006 | Recommended with restriction | no section in document |
| hydromorphone hydrochloride Treatment of chronic severe disabling pain not responding to non-narcotic analgesics, particularly for patients with opioid-responsive chronic pain of moderate… | Jul 2005 | Recommended with restriction | no section in document |
What the PBS pays
$696M in government benefit over 2024–25, across 15,533,719 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| buprenorphine | $182.7M |
| oxycodone hydrochloride + naloxone hydrochloride | $163.8M |
| oxycodone hydrochloride with naloxone hydrochloride dihydrate | $163.8M |
| oxycodone | $117.7M |
| tapentadol | $49.9M |
| fentanyl | $7.7M |
| fentanyl, transdermal patch | $7.7M |
| hydromorphone hydrochloride | $2.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.